Developing a novel recombinant antibody for treatment of oral cancer
开发用于治疗口腔癌的新型重组抗体
基本信息
- 批准号:8269866
- 负责人:
- 金额:$ 19.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAngiogenesis InhibitionAngiogenesis InhibitorsAntibodiesBindingBlocking AntibodiesCancer Cell GrowthCancer ModelCancer PatientCell ProliferationCell modelCetuximabClinicalClinical ResearchDNADeath RateDevelopmentDiagnosisDiseaseDistantDown-RegulationDrug Delivery SystemsEGFR Protein OverexpressionEngineeringEpidermal Growth Factor ReceptorFDA approvedFc ReceptorGenetic EngineeringGrowthHead and Neck CancerHypoxiaHypoxia Inducible FactorLaboratoriesLaboratory StudyLeadLinkMalignant NeoplasmsMediatingMetastatic LesionMonoclonal AntibodiesMusNeckNeoplasm MetastasisNutrientOperative Surgical ProceduresOrganOropharyngealOxygenPathway interactionsPatientsPharmaceutical PreparationsPilot ProjectsPlayPreventionPrimary NeoplasmProtein BiosynthesisProteinsRadiation therapyReceptor SignalingRecombinant AntibodyRecombinant ProteinsReportingRoleSignal TransductionSolid NeoplasmSquamous cell carcinomaStagingSurvival RateTechnologyTestingTimeTumor Cell InvasionUnited StatesValidationVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth FactorsVisionWorkXenograft ModelXenograft procedureangiogenesisbevacizumabcancer cellcancer diagnosiscancer therapycancer typecofactordisorder controlhypoxia inducible factor 1improvedinterestlymph nodesmalignant mouth neoplasmneoplastic cellnoveloutcome forecastoverexpressionpreventpromoterreceptorresponsetumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Oral cancer accounts for approximately 2% of all cancers diagnosed in the United States. Despite advances in therapy, the 5-year survival of patients with oral cancer has not significantly improved in decades, largely because metastases are usually present when oral cancer is diagnosed. Antiangiogenic therapy, such as therapy against vascular endothelial growth factor (VEGF), has been suggested as a potential treatment for oral cancer. However, currently approved antiangiogenic drugs have prolonged overall survival by only a few months in patients with other types of cancer. Furthermore, emerging evidence from laboratory and clinical studies indicates that, although antiangiogenic therapy inhibits the growth of primary tumors, it may also promote tumor invasion and metastasis owing to a hypoxia-inducible factor (HIF-1)-mediated adaptive-evasive response to worsening tumor hypoxia after successful antiangiogenic therapy. Therefore, it appears that a combination of antiangiogenic drugs with anti-HIF-1 drugs would be promising. Approximately 90% of oral cancers are squamous cell carcinoma, a subtype associated with overexpression of epidermal growth factor receptor (EGFR). Cetuximab, an EGFR-blocking antibody, is approved by the FDA in combination with radiotherapy for head and neck cancers, including oral cancers. We recently reported that cetuximab can decrease HIF-11 in both normoxic and hypoxic cancer cells. In this exploratory/developmental project, we propose to develop a novel recombinant antibody that targets both VEGF and EGFR. Our hypothesis is that a recombinant antibody that can inhibit VEGF-induced angiogenesis and also decrease the HIF-11 level through inhibition of the EGFR pathway in oral cancer works better than single-agent therapy with approved anti-VEGF or anti-EGFR drugs. We will test the hypothesis in oral cancer cell models in which both VEGF and EGFR are important promoters of cancer cell growth, invasion, and metastasis. We will compare the antitumor effects of our recombinant antibody with those of the FDA-approved anti-VEGF antibody bevacizumab and the FDA- approved anti-EGFR antibody cetuximab in terms of the impact on invasion and metastasis in metastatic oral cancer xenografts. We expect the proposed work to lead to development and validation of a novel recombinant antibody that not only inhibits growth of primary tumors but also prevents antiangiogenic therapy-induced invasion and metastasis. Such a novel recombinant antibody may significantly improve the 5-survival rate for patients with oral cancer through successful prevention and treatment of metastatic disease.
描述(由申请人提供):口腔癌约占美国所有癌症诊断的2%。尽管治疗取得了进步,但几十年来口腔癌患者的5年生存率并没有显著提高,这主要是因为口腔癌确诊时通常已经出现了转移。抗血管生成治疗,如抗血管内皮生长因子(VEGF)的治疗,已被认为是口腔癌的潜在治疗方法。然而,目前批准的抗血管生成药物只能将其他类型癌症患者的总生存期延长几个月。此外,来自实验室和临床研究的新证据表明,尽管抗血管生成治疗抑制原发肿瘤的生长,但它也可能促进肿瘤的侵袭和转移,这是由于抗血管生成治疗成功后,缺氧诱导因子(HIF-1)介导的对肿瘤缺氧恶化的适应性逃避反应。因此,抗血管生成药物与抗hif -1药物联合使用似乎是有希望的。大约90%的口腔癌是鳞状细胞癌,这是一种与表皮生长因子受体(EGFR)过表达相关的亚型。西妥昔单抗(Cetuximab)是一种egfr阻断抗体,已被FDA批准与放疗联合治疗头颈癌,包括口腔癌。我们最近报道了西妥昔单抗可以降低常氧和缺氧癌细胞中的HIF-11。在这个探索性/发展性项目中,我们建议开发一种新的靶向VEGF和EGFR的重组抗体。我们的假设是,在口腔癌中,一种重组抗体可以抑制vegf诱导的血管生成,并通过抑制EGFR途径降低HIF-11水平,比使用经批准的抗vegf或抗EGFR药物的单药治疗效果更好。我们将在口腔癌细胞模型中验证这一假设,其中VEGF和EGFR都是癌细胞生长、侵袭和转移的重要促进因子。我们将比较我们的重组抗体与FDA批准的抗vegf抗体贝伐单抗和FDA批准的抗egfr抗体西妥昔单抗在转移性口腔癌异种移植物侵袭和转移方面的抗肿瘤作用。我们希望这项工作能够开发和验证一种新的重组抗体,这种抗体不仅可以抑制原发肿瘤的生长,还可以防止抗血管生成治疗诱导的侵袭和转移。这种新型重组抗体可能通过成功的预防和治疗口腔癌转移,显著提高口腔癌患者的5-生存率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhen Fan其他文献
Zhen Fan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhen Fan', 18)}}的其他基金
Developing novel bispecific antibodies for cancer treatment
开发用于癌症治疗的新型双特异性抗体
- 批准号:
10441600 - 财政年份:2021
- 资助金额:
$ 19.75万 - 项目类别:
Developing novel bispecific antibodies for cancer treatment
开发用于癌症治疗的新型双特异性抗体
- 批准号:
10276280 - 财政年份:2021
- 资助金额:
$ 19.75万 - 项目类别:
Developing novel bispecific antibodies for cancer treatment
开发用于癌症治疗的新型双特异性抗体
- 批准号:
10659117 - 财政年份:2021
- 资助金额:
$ 19.75万 - 项目类别:
A novel targeted therapy for HNSCC based on a novel activity of cetuximab
基于西妥昔单抗新活性的 HNSCC 新型靶向治疗
- 批准号:
8827728 - 财政年份:2014
- 资助金额:
$ 19.75万 - 项目类别:
A novel targeted therapy for HNSCC based on a novel activity of cetuximab
基于西妥昔单抗新活性的 HNSCC 新型靶向治疗
- 批准号:
9020216 - 财政年份:2014
- 资助金额:
$ 19.75万 - 项目类别:
A novel targeted therapy for HNSCC based on a novel activity of cetuximab
基于西妥昔单抗新活性的 HNSCC 新型靶向治疗
- 批准号:
8697574 - 财政年份:2014
- 资助金额:
$ 19.75万 - 项目类别:
A novel targeted therapy for HNSCC based on a novel activity of cetuximab
基于西妥昔单抗新活性的 HNSCC 新型靶向治疗
- 批准号:
9229519 - 财政年份:2014
- 资助金额:
$ 19.75万 - 项目类别:
Developing a novel recombinant antibody for treatment of oral cancer
开发用于治疗口腔癌的新型重组抗体
- 批准号:
8095037 - 财政年份:2011
- 资助金额:
$ 19.75万 - 项目类别:
Mechanisms of tumor resistance to anti-HER/ErbB therapeutics
肿瘤对抗 HER/ErbB 治疗的耐药机制
- 批准号:
7466654 - 财政年份:2008
- 资助金额:
$ 19.75万 - 项目类别:
Mechanisms of tumor resistance to anti-HER/ErbB therapeutics
肿瘤对抗 HER/ErbB 治疗的耐药机制
- 批准号:
8212508 - 财政年份:2008
- 资助金额:
$ 19.75万 - 项目类别:
相似海外基金
Sexual dimorphism in antigen-independent angiogenesis inhibition of IgG1 antibodies
IgG1 抗体的抗原非依赖性血管生成抑制中的性别二态性
- 批准号:
10536062 - 财政年份:2022
- 资助金额:
$ 19.75万 - 项目类别:
Sexual dimorphism in antigen-independent angiogenesis inhibition of IgG1 antibodies
IgG1 抗体的抗原非依赖性血管生成抑制中的性别二态性
- 批准号:
10705615 - 财政年份:2022
- 资助金额:
$ 19.75万 - 项目类别:
Structure-activity relationship study on the tumor angiogenesis inhibition activity of fucoidan
岩藻依聚糖抑制肿瘤血管生成活性的构效关系研究
- 批准号:
18K05455 - 财政年份:2018
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tumor angiogenesis inhibition by regulation of reactive oxygen species
通过调节活性氧抑制肿瘤血管生成
- 批准号:
16K20555 - 财政年份:2016
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
A novel treatment strategy of angiogenesis inhibition targeting for aquaporin-1 in intractable benign brain tumors
一种针对水通道蛋白-1的血管生成抑制治疗难治性良性脑肿瘤的新策略
- 批准号:
25462248 - 财政年份:2013
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The analysis of angiogenesis inhibition by PEDF using collagen-like triple helical peptides
使用类胶原三螺旋肽的 PEDF 抑制血管生成的分析
- 批准号:
24810026 - 财政年份:2012
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Tumour suppressor mediated mechanisms of angiogenesis inhibition
肿瘤抑制因子介导的血管生成抑制机制
- 批准号:
224817 - 财政年份:2011
- 资助金额:
$ 19.75万 - 项目类别:
Operating Grants
EFFECT OF ANGIOGENESIS INHIBITION ON TRANSARTERIAL TUMOR EMBOLIZATION IN RAT
血管生成抑制对大鼠经动脉肿瘤栓塞的影响
- 批准号:
7956931 - 财政年份:2009
- 资助金额:
$ 19.75万 - 项目类别:
Identification of novel mechanisms of angiogenesis inhibition by p53
鉴定 p53 抑制血管生成的新机制
- 批准号:
184697 - 财政年份:2008
- 资助金额:
$ 19.75万 - 项目类别:
Studentship Programs
Signaling of intrinsic angiogenesis inhibition in cancer tissues
癌症组织中内在血管生成抑制的信号传导
- 批准号:
17014006 - 财政年份:2005
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Scientific Research on Priority Areas